Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.66 |
| ▸ | HTR1A | P08908 | 11/20 | 0.66 |
| ▸ | HTR6 | P50406 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | HTR1D | P28221 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908691 | 0.89 | HTR7 (0.66) | HTR7HTR1AHTR6HTR2AHTR1D | |
| SCHEMBL4914478 | 0.88 | HTR7 (0.59) | HTR7HTR1AHTR6HTR2AHTR1D | |
| SCHEMBL4907297 | 0.86 | HTR2C (0.63) | HTR7HTR1AHTR6HTR2AHTR1D | |
| SCHEMBL4913526 | 0.85 | ADRB1 (0.63) | HTR7HTR1AHTR6HTR2AHTR1D | |
| SCHEMBL4912823 | 0.84 | HTR7 (0.69) | HTR7HTR1AHTR6HTR2AHTR1D | |
| SCHEMBL315894 | 0.83 | HTR7 (0.68) | HTR7HTR1AHTR6HTR2AHTR1D | |
| Hydrochloric Acid SCHEMBL9743614 | 0.82 | HTR7 (0.66) | HTR7HTR1AHTR6HTR2AHTR1D | |
| Hydrochloric Acid SCHEMBL11556656 | 0.82 | HTR7 (0.66) | HTR7HTR1AHTR6HTR2AHTR1D | |
| Bromide SCHEMBL6774182 | 0.82 | HTR7 (0.66) | HTR7HTR1AHTR6HTR2AHTR1D | |
| Bromide SCHEMBL27376788 | 0.80 | HTR7 (0.64) | HTR7HTR1AHTR6HTR2AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | claimed |
| US-20210052600-A1 | THERAPEUTIC AGENTS FOR STRESS URINARY INCONTINENCE AND INCOTINENCE OF FECES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| EP-3733204-A1 | THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| EP-1828156-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006065600-A2 | N-BIARYL AND N-ARYLHETEROARYL PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119477-A1 | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | HTR7 10/4885HTR1A 9/4885HTR6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.